BWP
ONCT

Balboa Wealth Partners’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Balboa Wealth Partners’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,375
Closed -$25.5K – 325
2023
Q4 		$25.5K Hold
2,375
– – 0.01% 269
2023
Q3 		$14.3K Hold
2,375
– – 0.01% 276
2023
Q2 		$16.4K Buy
2,375
+1,500
+171% +$9.89K 0.01% 292
2023
Q1 		$13.7K Hold
875
– – 0.01% 292
2022
Q4 		$17.5K Hold
875
– – 0.01% 273
2022
Q3 		$16K Buy
+875
New +$18.8K 0.01% 252

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balboa Wealth Partners's ONCT Position: Q1 2024 in Review

Balboa Wealth Partners sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2024, closing a stake of 2,375 shares — an estimated $25.5K sold.

Balboa Wealth Partners first reported a position in ONCT in Q3 2022 and held it in 6 quarters. The position peaked at $25.5K in Q4 2023. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.

  • Balboa Wealth Partners reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Balboa Wealth Partners sold 2,375 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $25.5K.
  • Balboa Wealth Partners first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q3 2022 and held it in 6 quarters.
  • Balboa Wealth Partners's Oncternal Therapeutics, Inc. Common Stock position peaked at $25.5K in Q4 2023.
  • 24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Balboa Wealth Partners's 13F filing for Q1 2024, filed 13 May 2024.